What is the difference between CGRP and GLP-2?

CGRP: Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. GLP-2: Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth.

Is CGRP FDA approved?

CGRP is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is GLP-2 FDA approved?

GLP-2 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is CGRP administered in research settings?

In research settings, CGRP is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is GLP-2 administered in research settings?

In research settings, GLP-2 is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CGRP vs GLP-2

Peptide Comparison

CGRP vs GLP-2

Both are Tissue Repair peptides.

CGRP

Calcitonin Gene-Related Peptide

RecoveryNot EvaluatedResearch Only

Half-life: ~3.6 min / ~13.6 min (biphasic; sheep)

2 providers listed

Full CGRP profile →

GLP-2

Glucagon-like Peptide-2

RecoveryNot EvaluatedResearch Only

11 providers listed

Full GLP-2 profile →

Bottom line

GLP-2 is carried by more providers on PeptideBase (11 vs 2); otherwise the two are closely matched on the measures we track.

Quick Verdict

CGRP

Half-life

~3.6 min / ~13.6 min (biphasic; sheep)

GLP-2

Half-life

—

Which One Should You Choose?

Your goal	Better option
More provider options (2 vs 11)	GLP-2

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CGRP

GLP-2

Mechanism Family

Tissue Repair

Half-life

~3.6 min / ~13.6 min (biphasic; sheep)

—

FDA Status

not evaluated

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Providers

2 listed

11 listed

Avail. Notes

Native CGRP is not an FDA-approved drug substance; an openFDA ingredient search for "calcitonin gene-related" returns no approved product. The CGRP pathway is a validated migraine target, but via receptor ANTAGONISTS — erenumab (Aimovig, BLA 761077, approved 2018-05-17) and the gepants — not via CGRP itself. The 2018-05-17 date previously carried on this record was erenumab's approval date and has been removed.

Native GLP-2 is not an FDA-approved drug substance; an openFDA ingredient search for "glucagon-like" returns no approved product. The approved product is teduglutide (Gattex, NDA 203441, original approval 2012-12-21), a 33-amino-acid ANALOG of human GLP-2 — see the separate teduglutide profile. The 2012-08-30 date previously carried on this record corresponds to no locatable FDA approval action and has been removed.

Research Evidence

CGRP

RCT · 10 key studies · most recent 2026

GLP-2

RCT · 7 key studies · most recent 2026

Research Citations

CGRP

RCT2018 · Lancet

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous prevent…

RCT2017 · New England Journal of Medicine

A Controlled Trial of Erenumab for Episodic Migraine

Cohort2026 · Front Neurol

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin ge…

Animal2026 · J Physiol

Functional role of Nav1.8 channels in action potentials of mouse CGRP-lineage dorsal root ganglion neurons.

+6 more

GLP-2

RCT2018 · Nutrition in Clinical Practice

Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Pa…

Case series2026 · JPGN Rep

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

Cohort2026 · Clin Nutr

From childhood to adulthood in chronic intestinal failure: A nationwide study.

Cohort2026 · Clin Nutr

Impact of intestinal resections on the secretion of gastrointestinal hormones.

+3 more

About CGRP

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

Research Areas

vasodilationpain modulationwound healingbone repair

About GLP-2

Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Strengthens tight junctions and reduces intestinal permeability.

Research Areas

gut lining repairintestinal integritybarrier functionanti-inflammatory

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CGRP

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

GLP-2

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

CGRP

2 listed

Browse directory →

Providers offering

GLP-2

11 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.